- Published at
- by investing.com
positive
positive
ZVRA stock touches 52-week high at $8.96 amid market rally By Investing.com
ZVRA stock touches 52-week high at $8.96 amid market rally
News for KemPharm, Inc. (KMPH)
- Published at
- by investing.com
positivepositiveEarnings call: Zevra Therapeutics reports progress and financials for Q4 2023 By Investing.com
Earnings call: Zevra Therapeutics reports progress and financials for Q4 2023- Published at
- by globenewswire.com
neutralneutralZevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare...- Published at
- by benzinga.com
neutralneutralZevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 - Zevra Therapeutics (NASDAQ:ZVRA)
CELEBRATION, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, announced its expected addition to the- Published at
- by globenewswire.com
neutralneutralZevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare...- Published at
- by globenewswire.com
positivepositiveZevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
Zevra plans to expand KP1077 clinical program to address multiple rare sleep disorders with trials initiating in 2023 CELEBRATION, Fla., May 03, 2023 ...- Published at
- by globenewswire.com
neutralneutralLeading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy
Glass Lewis Recommends a Vote “FOR” Zevra’s Three Nominees Both ISS and Glass Lewis Recommend Shareholders DO NOT Vote “FOR” Any of the Mangless...- Published at
- by globenewswire.com
neutralneutralZevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Zevra...- Published at
- by prnewswire.com
mixedmixedCentral nervous system (CNS) stimulant drugs market size to grow by USD 6,486.71 million between 2022 and 2027; Growth driven by the rise in CNS disorders - Technavio
/PRNewswire/ -- The central nervous system (CNS) stimulant drugs market size is forecast to increase by USD 6,486.71 million from 2022 to 2027, at a CAGR of...- Published at
- by globenewswire.com
mixedmixedZevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare...- Published at
- by globenewswire.com
mixedmixedCORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to...- Published at
- by etfdailynews.com
positivepositiveContrasting Abliva AB (publ) (OTCMKTS:NEVPF) and KemPharm (NASDAQ:KMPH)
Read Contrasting Abliva AB (publ) (OTCMKTS:NEVPF) and KemPharm (NASDAQ:KMPH) at ETF Daily News- Published at
- by etfdailynews.com
mixedmixedInvestment Analysts’ Upgrades for May 24th (CAHPF, CCU, DNNGY, DOX, EOG, FNA, FREE, FXTGY, GBNH, GEGYY)
Read Investment Analysts’ Upgrades for May 24th (CAHPF, CCU, DNNGY, DOX, EOG, FNA, FREE, FXTGY, GBNH, GEGYY) at ETF Daily NewsXGGB.MCTRVC.DESNOWSKUFFSKTSKFRYSCVLPPTA.TOPPTAPDAC-UNPDACMETCMASSMARALXP-PCLXPLSCCLMBLICYKZRKMPHJPMMLJPMCL.SNJPMC.BAJPMIRDMINGILALHTGCHSM.TOHSKAHSDTWHSDTGTMS.TOGGBR4.SAGGBR3.SAGGBN.MXGGB.BAGGBGEGYYGBOKFGBNHFXTGYFREEWFREEFOXT.LEVN.AXDNNGYCAHPFC.MXC.BAC0NWW.LVCVCWVCVCUVCVCUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSSNBPREEPTSIPGCPBLAORSTEDN.MXMOH.DEMDRPFMCN.MXMC.PAMAX.TOLVMUYLVMHFLVMH.MILGL-WTLGLLABPKDNYJEF.MXJEFJDN.MXJDCO34.SAJDCMFJD.BAJDJCSINABHEPAGRTXGENL.LGEGYFEOGDOXDOGEF9618.HKOTISMQBCY.DEBCSN.MXBCS.BABCSBCLYFBARC.L- Published at
- by etfdailynews.com
mixedmixedInvestment Analysts’ Downgrades for May 17th (ACXIF, ADBE, AGYS, ALLT, ATRA, AUTO, AVYA, BNS, CM, CMWAY)
Read Investment Analysts’ Downgrades for May 17th (ACXIF, ADBE, AGYS, ALLT, ATRA, AUTO, AVYA, BNS, CM, CMWAY) at ETF Daily NewsWDAYUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSSOLOSOLSNOWD.BASNOW.MXSNOW.BASNOWSMTCSMSISFSTS2NW34.SARGLSRDNTPDLBOPIUSA.MXOPINLOPINIOPIOKTA.MXOKTAO1KT34.SANOAHMPCMAXRLZLSCCKMPHKALVIVA.PAIVAITRIHSTHL.BAHL-PBHLHGVHCL.DEGSGI34.SAGS.MXGS.BAGSGOVGOS.DEGLNCYGLN.JOGLENN.MXGLEN.LGLCNFGENIFRBAFBSIDMYT-UNDMYTDMYD-UNDMYDCPSSCMTV0RNK.L0R0A.L0KB7.L0IVW.LTAPSTARSRACWSRACUSRACSCMRYRAILNSH-WTNSH-UNNSHNGLMRMDMQMNTSMMATMFCJOUTJEF.MXJEFJBLIEAICADHLDVFHLDCYCPTCMWAYCM.TOCMCCIXFCBAUFCBAPJ.AXBCY.DEBCSN.MXBCS.BABCSBCLYFBARC.LAUTOATRAAGYS0UNI.L0012.HKTGASFPSOMMHTFHOKCYHOKCFHDVTY1083.HK0097.HK0071.HK0050.HK0003.HK- Published at
- by etfdailynews.com
mixedmixedInvestment Analysts’ Upgrades for May 11th (ADDYY, AHT, ARCT, ARTNA, ARWR, ASHTY, AZEK, BNCDY, CELH, CLB)
Read Investment Analysts’ Upgrades for May 11th (ADDYY, AHT, ARCT, ARTNA, ARWR, ASHTY, AZEK, BNCDY, CELH, CLB) at ETF Daily NewsVUZIUSAUUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSTIXTTHCBWTHCBUTHCBTHBRWTHBRUTHBRTCBKSXS.LSXISUMOSRRKSPXSYSPXSFSPX.LSPSOLOSNPOSKYTSGIOYSGIOFSGBAFSESG.PASERASEPJYSEPJFSCVLSCORSAILRXDXRPDROADPWFL.TAPWFLPUKPFPUK-WIPUK-PPUKPTONPRU.LPRU.DEPNTGPKOHPGTIPDYPYPDYPFOYSTONCRNSKFFNOVTNLSNIUN.MXNIUNGMSNCLTYNCLTFMYOMUXMLNKMLCOMKTWLSFLICYKOPNKOGO.OLKNOPKMPHJNCEJEF.MXJEFIRIXINVAHPPHIMS-WTHIMSHGVHBIOGSBDGERNGEGGECCLGECCGECFOJCYFOJCFFLTR.LETTYFADSN.MXADS.MIADS.DEADDYYADDDFACND-UNACND9843.T4507.T2378.HK0RQC.L0LHW.L0KTX.L0JRR.L0A9A.L0A54.LTHRYTCRXTACTSWBISUPNSPNV-WTSPNV-UNSPNVSELBRYRXTPDAC-UNPDACOXSQOTTROTLYOPRTOPADOFSSGOFSOAC-UNOACNKLA.MXNGLMGTAMAINLIFEKROSIKNAIFSICVXHZON-WTHZAC-WTHZAC-UNHZACHSWLFHLHITIFHITIDHITI.VHITIGXE.DEGSKGOROGMTXGLPGFGLPG.ASGLPGFSDCEGHTEADBK.PRDBK.MIDBCWGRPCSN.MXCSGNE.SWCSGN.SWCSGKFCSCRONCOWNLCOWNCMICLBCF.TOCCXCCORFASHTYARWRARTNAAOUT8NI.DE0LB2.L0JXQ.L0IYS.L0I4P.L0HEM.L0A3R.LPLNTJPMMLJPMCAHCWCAHCUCAHC- Published at
- by etfdailynews.com
mixedmixedEquities Research Analysts’ Downgrades for April 20th (ACC, AGYS, ATRS, BBBY, CMPI, DUAVF, EGLE, FBBPF, GOGL, HAL)
Read Equities Research Analysts’ Downgrades for April 20th (ACC, AGYS, ATRS, BBBY, CMPI, DUAVF, EGLE, FBBPF, GOGL, HAL) at ETF Daily NewsYVXRT.MXVXRTVTXPFVSTAVMIVETVCT.LUFIUFCSTWODYTWODFTW.LTMHCTELLSWRBYSWRBFSWRAYSWRAFSUBCYSUBCO.OLSUBC.OLSTEM.LSSL.TOSSDSPXSYSPXSFSPX.LSITESHENSGPYYSGGEFSGE.LSFSHFSDFN.MXSDF1.DESDF.MISDF.DESANDSAFE.LRICKQUIKPENPDFSOTTROPIUSA.MXOPINLOPINIOPIOOMANUENTBNBSENB11.DEMYGNMRSNMRMDMOSMANLZLU2.DELITE.MXLITELGIHLFUSLCNBKPLUYKPLUFKMPHINVHHSBC.BAHSBC-PAHSBCHSBA.LHSB.PAHBCYFHBCN.MXHBC1.DEH1SB34.SAGOVATRSACGYF0VGM.L0LE3.L0JVV.L0JSI.L0A4Q.L0087.HK0019.HK0005.HKVSTOUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSUBABTVTXTRVC.DETRIPTLKMFTLKTALN.MXTALT1LK34.SASMEDSLGCSBLKSAIARYRTRXPWRPNNTPLLPFXNLPFXPFLT.TAPFLTNTICNKTRNKSHNFLXNEMNDEKYNDEKFMRCMEECMCSLSCCKLR-WTKLRKGCJPSWYJAKKJITRGITR.VIAGHALDBN.MXDBK.PRDBK.MIDBK.DEDBCMIIWCMIIUCMIIC.MXC.BACBBBYAGYSACC6988.T0UNL.L0KT6.LWFCRMGBWRMGBURMGBPAVMWPAVMOPYMXDHFMDXH.BRMDJPMMLJPMCL.SNJPMC.BAJPMGOGLFIBRAPL14.MXFBBPFEGLEDUAVFCMPI0O8G.L- Published at
- by thestreet.com
mixedmixedGlobal Drug Delivery Systems (DDS) Markets 2021-2027 - Increasing R&D Expenditures Of Innovator Companies And The Trend Of Patent Portfolio Expansion
DUBLIN, July 29, 2021 /PRNewswire/ -- TheVXRT.MXVXRTTMO.MXTMOTLCTFFPSPL.AXSPHRYSPHRFPFED.BAPFECL.SNPFE.MXPFE.DEPFENVSN.MXNVSEFNVSD.BANVSNOVN.SWNB11.DEN1VS34.SAAMGN.MXAMGN.BAAMGNAMG.DE0R0H.L0K9E.LMYMXMTLHYMTLHFMRSNMGFRFMF6.DELZAGYLZAGFLONN.SWLGNDKMPHHYDIHALOGRAGIS.DEGILDD.BAGILD.MXGILDFUJIYFUJIFEVKIYEVKIFEVK.DEBPTHBFFAFBASN.MXBASFYBASF.MIBASF.BDBASA.DEBAS.DEARCTAQSTALT1.MXALTABBV34.SAABBV.MXABBV.BAABBV4AB.DE4901.T4188.T196170.KQ0QNO.L0J2O.L0A4C.LPCRXOSMTCTLT- Published at
- by insidermonkey.com
mixedmixed- Published at
- by tradersinsight.news
mixedmixedThe Daily Biotech Pulse: April 9, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs- Published at
- by rttnews.com
mixedmixedKMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent
Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.